Business Context and Reporting Period
Company: Humana Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 29, 2025
Reporting Period: Full Year 2025 (FY 2025) guidance reaffirmation.
Context: The filing serves as a Regulation FD disclosure regarding upcoming investor meetings scheduled between September 1, 2025, and September 30, 2025, where management intends to reaffirm its full-year financial guidance.
Key Financial Metrics
The filing provides forward-looking guidance for FY 2025 but does not contain historical revenue, profit, cash flow, or debt figures for the current or prior periods.
| Metric | Value (FY 2025 Guidance) |
|---|---|
| GAAP Diluted EPS | Approximately $13.77 |
| Adjusted (Non-GAAP) EPS | Approximately $17.00 |
Note: The filing does not provide clear values for total revenue, operating margins, cash flow, debt levels, or liquidity metrics.
Material Changes and Reconciliation
The filing details the reconciliation between GAAP and Adjusted EPS guidance, highlighting specific non-GAAP adjustments:
- Amortization of identifiable intangibles: $0.49
- Put/call valuation adjustments: $3.01 (associated with non-consolidating minority interest investments)
- Value creation initiatives: $0.44
- Impairment charges: $0.26
- Cumulative net tax impact: ($0.97)
The guidance is consistent with the press release issued on July 30, 2025. The filing explicitly states that the guidance excludes the impact of future value changes to items that are not yet probable or cannot be reasonably estimated.
Guidance, Outlook, and Risks
Guidance Reaffirmation: Management intends to reaffirm the FY 2025 EPS targets of $13.77 (GAAP) and $17.00 (Adjusted) during upcoming investor meetings.
Medicare Advantage Star Ratings: The Company will not comment on 2026 Medicare Advantage (MA) Star Ratings (Bonus Year 2027) until the Centers for Medicare and Medicaid Services (CMS) releases final data in October 2025.
Risks and Contingencies: The filing includes a standard cautionary statement regarding forward-looking statements, noting they are subject to risks, uncertainties, and assumptions detailed in the "Risk Factors" section of other SEC filings. No specific new risks or contingencies were detailed in this text.
Investor Verification Checklist
- Verify the final 2026 Medicare Advantage Star Ratings data release by CMS in October 2025 to assess potential impacts on 2027 bonus year performance.
- Review the July 30, 2025, press release and Q2 2025 earnings call transcript for the original context of the $13.77 GAAP and $17.00 Adjusted EPS guidance.
- Monitor upcoming investor meetings (September 1–30, 2025) for any updates or deviations from the reaffirmed guidance.
- Examine the reconciliation of GAAP to Adjusted EPS in future filings to track the actual realization of the $3.01 put/call valuation adjustments and other non-GAAP items.